Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to $9.8 million.

  • Immunocore Holdings' Share-based Compensation rose 4997.71% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 1623.77%. This contributed to the annual value of $34.2 million for FY2024, which is 530.04% up from last year.
  • Immunocore Holdings' Share-based Compensation amounted to $9.8 million in Q3 2025, which was up 4997.71% from $10.0 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Share-based Compensation peaked at $10.0 million during Q2 2025, and registered a low of $6.6 million during Q3 2024.
  • For the 3-year period, Immunocore Holdings' Share-based Compensation averaged around $8.7 million, with its median value being $8.8 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 2000.24% in 2024, then surged by 4997.71% in 2025.
  • Over the past 3 years, Immunocore Holdings' Share-based Compensation (Quarter) stood at $7.2 million in 2023, then grew by 20.53% to $8.7 million in 2024, then grew by 13.5% to $9.8 million in 2025.
  • Its last three reported values are $9.8 million in Q3 2025, $10.0 million for Q2 2025, and $9.5 million during Q1 2025.